Drug intelligence / Profile preview

mefuparib

Development stage: Phase 2
Lead developer: Convalife Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Mefuparib (CVL218) is a small molecule poly (ADP-ribose) polymerase (PARP) inhibitor, specifically targeting PARP1 and PARP2. Developed by Convalife Pharmaceutical, it is designed to treat various malignancies by inhibiting DNA repair mechanisms, leading to synthetic lethality in cells with existing DNA repair deficiencies, such as those with BRCA mutations. It is currently being evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors, including glioma, cholangiocarcinoma, and pancreatic cancer. Beyond oncology, mefuparib has also been investigated for its potential in treating COVID-19 due to its ability to inhibit viral replication and modulate inflammatory responses.

Brand names: Convalife
Other names: mefuparib hydrochloride

Targets

PARP1 (Poly (adp-ribose) polymerase 1)PARP2 (Poly (adp-ribose) polymerase 2)

Beyond the preview

Go deeper on mefuparib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mefuparib.